The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Structural basis for antagonism and resistance of bicalutamide in prostate cancer
Open accessAbstract
Carcinoma of the prostate is the most commonly diagnosed cancer in men. The current pharmacological treatment of choice for progressive androgen-dependent prostate cancer is the nonsteroidal antiandrogen, bicalutamide, either as monotherapy or with adjuvant castration or luteinizing hormone-releasing hormone superagonists to block the synthesis of endogenous testosterone. To date, no nonsteroidal or antagonist-bound androgen receptor (AR) structure is available. We solved the x-ray crystal structure of the mutant W741L AR ligand-binding domain bound to R -bicalutamide at 1.8-Å resolution. This mutation confers agonist activity to bicalutamide and is likely involved in bicalutamide withdrawal syndrome. The three-dimensional structure demonstrates that the B ring of R -bicalutamide in the W741L mutant is accommodated at the location of the indole ring of Trp-741 in the WT AR bound to dihydrotestosterone. Knowledge of the binding mechanism for R -bicalutamide will provide molecular rationale for the development of new antiandrogens and selective AR modulators.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures
Kraulis, P. J. (1991) · Journal of Applied Crystallography · doi:10.1107/s0021889891004399 · Cited by 14,085
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
Raster3D Version 2.0. A program for photorealistic molecular graphics
Merritt, E. A., & Murphy, M. E. P. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994006396 · Cited by 2,504
Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor
Matias, P. M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, P., Wegg, A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004571200 · Cited by 608
Sack, J. S., Kish, K. F., Wang, C., Attar, R. M., Kiefer, S. E., An, Y., Wu, G. Y., Scheffler, J. E., Salvati, M. E., Krystek, S. R., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081565498 · Cited by 491
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara, T., Miyazaki, J., Araki, H., Yamaoka, M., Kanzaki, N., Kusaka, M., & Miyamoto, M. (2003) · PubMed · Cited by 425
He, B., Gampe, R. T., Kole, A. J., Hnat, A. T., Stanley, T. B., An, G., Stewart, E. L., Kalman, R. I., Minges, J. T., & Wilson, E. M. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.09.036 · Cited by 295
Masiello, D., Cheng, S., Bubley, G. J., Lu, M. L., & Balk, S. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203310200 · Cited by 240
Recognition and Accommodation at the Androgen Receptor Coactivator Binding Interface
Hur, E., Pfaff, S. J., Payne, E. S., Grøn, H., Buehrer, B. M., & Fletterick, R. J. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020274 · Cited by 234
See, W. A., Wirth, M. P., McLeod, D. G., Iversen, P., Klimberg, I., Gleason, D., Chodak, G., Montie, J., Tyrrell, C., Wallace, D. M. A., et al. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64652-6 · Cited by 230
Discovery of Nonsteroidal Androgens
Dalton, J. T., Mukherjee, A., Zhu, Z., Kirkovsky, L., & Miller, D. D. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8209 · Cited by 226
Self-citationWIRTH, M. P., SEE, W. A., McLEOD, D. G., IVERSEN, P., MORRIS, T., CARROLL, K., & ON BEHALF OF THE CASODEX EARLY PROSTATE CANCER TRIALISTS' GROUP (2004) · Journal of Urology · doi:10.1097/01.ju.0000140159.94703.80 · Cited by 209
Suzuki, H., Akakura, K., Komiya, A., Aida, S., Akimoto, S., & Shimazaki, J. (1996) · The Prostate · doi:10.1002/1097-0045(199609)29:3<153::aid-pros2990290303>3.0.co;2-5 · Cited by 208
Smith, M. R., Goode, M., Zietman, A. L., McGovern, F. J., Lee, H., & Finkelstein, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.174 · Cited by 188
Hormone-refractory (D3) prostate cancer: Refining the concept
Scher, H. I., Steineck, G., & Kevin Kelly, W. (1995) · Urology · doi:10.1016/s0090-4295(99)80182-4 · Cited by 176
Gao, W., Kearbey, J. D., Nair, V. A., Chung, K., Parlow, A. F., Miller, D. D., & Dalton, J. T. (2004) · Endocrinology · doi:10.1210/en.2004-0627 · Cited by 143
Self-citationMarhefka, C. A., Gao, W., Chung, K., Kim, J., He, Y., Yin, D., Bohl, C. E., Dalton, J. T., & Miller, D. D. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030336u · Cited by 136
Self-citationTucker, H., Crook, J. W., & Chesterson, G. J. (1988) · Journal of Medicinal Chemistry · doi:10.1021/jm00400a011 · Cited by 130
Key Structural Features of Nonsteroidal Ligands for Binding and Activation of the Androgen Receptor
Yin, D., He, Y., Perera, M. A., Hong, S., Marhefka, C. A., Stourman, N. V., Kirkovsky, L. I., Miller, D. D., & Dalton, J. T. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.1.211 · Cited by 124
Self-citationA Selective Androgen Receptor Modulator for Hormonal Male Contraception
Chen, J., Hwang, D., Bohl, C. E., Miller, D. D., & Dalton, J. T. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075424 · Cited by 101
Self-citationIversen, P., Johansson, J., Lodding, P., Lukkarinen, O. A., Lundmo, P. I., Klarskov, P., Tammela, T. L. J., Taşdemir, İ., Morris, T., Carroll, K., et al. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000139719.99825.54 · Cited by 98
Matias, P. M., Carrondo, M. A., Coelho, R., Thomaz, M., Zhao, X.-Y., Wegg, A., Crusius, K., Egner, U., & Donner, P. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011072j · Cited by 98
Bicalutamide (Casodex®) in the treatment of prostate cancer
Fradet, Y. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.1.37 · Cited by 92
Bohl, C. E., Chang, C. K., Mohler, M. L., Chen, J., Miller, D. D., Swaan, P. W., & Dalton, J. T. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0499007 · Cited by 81
Self-citationAkaza, H. (2004) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyh001 · Cited by 80
Worldwide activity and safety of bicalutamide: a summary review
Kolvenbag, G. J. C. M., & Blackledge, G. R. P. (1996) · Urology · doi:10.1016/s0090-4295(96)80012-4 · Cited by 66
Expression of CD44 isoforms in human prostate tumor cell lines
Stevens, J. W., Palechek, P. L., Griebling, T. L., Midura, R. J., Rokhlin, O. W., & Cohen, M. B. (1996) · The Prostate · Cited by 46
Bicalutamide Monotherapy for Early Stage Prostate Cancer: An Update
Iversen, P. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000096491.61731.38 · Cited by 20
Relative potency of bicalutamide (Casodex) and flutamide (Eulexin)
Schellhammer, P., & Fabozzi, S. (1999) · PubMed · Cited by 14
Cited by
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
Fleming, F. F., Yao, L., Ravikumar, P. C., Funk, L., & Shook, B. C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100762r · Cited by 1,754
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Androgen receptor: structure, role in prostate cancer and drug discovery
Tan, M. E., Li, J., Xu, H. E., Melcher, K., & Yong, E.-L. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.18 · Cited by 943
Diverse, High-Quality Test Set for the Validation of Protein−Ligand Docking Performance
Hartshorn, M. J., Verdonk, M. L., Chessari, G., Brewerton, S. C., Mooij, W. T. M., Mortenson, P. N., & Murray, C. W. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061277y · Cited by 625
Metadata
- Authors
- Bohl, C. E., Gao, W., Miller, D. D., Bell, C. E., & Dalton, J. T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-04-15
- Volume
- 102
- Issue
- 17
- Pages
- 6201-6206
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2006138763
- Cited by
- 421
- References
- 30
- FWCI
- 18.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.